EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clinical Uses of Inhaled Antifungals for Invasive Pulmonary Fungal Disease: Promises and Challenges

Nancy N Vuong iD, Danielle Hammond, Dimitrios P Kontoyiannis iD

Journal of Fungi · 12.04.2023 · 9 (4) · 464

DOI: 10.3390/jof9040464 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Fungi, online erschienen am 12.04.2023. Verfasst von Nancy N Vuong und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The role of inhaled antifungals for prophylaxis and treatment of invasive fungal pneumonias remains undefined. Herein we summarize recent clinically relevant literature in high-risk groups such as neutropenic hematology patients, including those undergoing stem cell transplant, lung and other solid transplant recipients, and those with sequential mold lung infections secondary to viral pneumonias. Although there are several limitations of the available data, inhaled liposomal amphotericin B administered 12.5 mg twice weekly could be an alternative method of prophylaxis in neutropenic populations at high risk for invasive fungal pneumonia where systemic triazoles are not tolerated. In addition, inhaled amphotericin B has been commonly used as prophylaxis, pre-emptive, or targeted therapy for lung transplant recipients but is considered as a secondary alternative for other solid organ transplant recipients. Inhaled amphotericin B seems promising as prophylaxis in fungal pneumonias secondary to viral pneumonias, influenza, and SARS CoV-2. Data remain limited for inhaled amphotericin for adjunct treatment, but the utility is feasible.

Schlagwörter

Stichwörter der Autor:innen

amphotericin Bantifungalaspergillosisfungal pneumoniainhaled

Autor:innen und Institutionen

  • Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Infectious Disease, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

ORCID-Profile: Nancy N Vuong, Dimitrios P Kontoyiannis

Zitieren

APA

Vuong, N. N., Hammond, D., & Kontoyiannis, D. P. (2023). Clinical Uses of Inhaled Antifungals for Invasive Pulmonary Fungal Disease: Promises and Challenges. Journal of Fungi, 9(4), 464. https://doi.org/10.3390/jof9040464

Vancouver

Vuong NN, Hammond D, Kontoyiannis DP. Clinical Uses of Inhaled Antifungals for Invasive Pulmonary Fungal Disease: Promises and Challenges. Journal of Fungi. 2023;9(4):464. doi:10.3390/jof9040464

BibTeX
@article{Vuong2023,
  author = {Vuong, Nancy N and Hammond, Danielle and Kontoyiannis, Dimitrios P},
  title = {Clinical Uses of Inhaled Antifungals for Invasive Pulmonary Fungal Disease: Promises and Challenges},
  journal = {Journal of Fungi},
  year = {2023},
  volume = {9},
  number = {4},
  pages = {464},
  doi = {10.3390/jof9040464}
}
Kostenlos starten →